US 11,723,921 B2
Modulated immunodominance therapy
Alfred E. Slanetz, Cohasset, MA (US)
Assigned to GENEIUS BIOTECHNOLOGY, INC., Natick, MA (US)
Filed by Geneius Biotechnology, Inc., Natick, MA (US)
Filed on Apr. 13, 2017, as Appl. No. 15/486,864.
Application 15/486,864 is a continuation of application No. 14/122,036, abandoned, previously published as PCT/US2012/039605, filed on May 25, 2012.
Claims priority of provisional application 61/490,505, filed on May 26, 2011.
Prior Publication US 2017/0216357 A1, Aug. 3, 2017
Int. Cl. A61K 35/17 (2015.01); A61K 39/00 (2006.01); A61K 39/29 (2006.01); A61K 39/12 (2006.01); A61K 39/245 (2006.01); C12N 7/00 (2006.01); A61K 9/00 (2006.01); C12N 5/0783 (2010.01); A61K 35/12 (2015.01)
CPC A61K 35/17 (2013.01) [A61K 9/0019 (2013.01); A61K 9/0021 (2013.01); A61K 39/0008 (2013.01); A61K 39/0011 (2013.01); A61K 39/12 (2013.01); A61K 39/245 (2013.01); A61K 39/292 (2013.01); C12N 5/0636 (2013.01); C12N 7/00 (2013.01); A61K 2035/124 (2013.01); A61K 2039/5158 (2013.01); A61K 2039/53 (2013.01); A61K 2039/55566 (2013.01); A61K 2039/585 (2013.01); C12N 2501/2302 (2013.01); C12N 2501/2304 (2013.01); C12N 2501/2306 (2013.01); C12N 2501/2307 (2013.01); C12N 2501/2312 (2013.01); C12N 2501/2315 (2013.01); C12N 2501/2321 (2013.01); C12N 2501/999 (2013.01); C12N 2710/16034 (2013.01); C12N 2710/16234 (2013.01); C12N 2730/10134 (2013.01); C12N 2730/10171 (2013.01)] 12 Claims
 
1. A method for making a T cell population for use in altering the immunodominance hierarchy of a patient, comprising the steps of:
a. identifying at least one subdominant antigen or subdominant epitope in a sample obtained from the patient whose immunodominance hierarchy is to be altered, wherein the at least one subdominant antigen or subdominant epitope evokes a weaker tolerance or immune response than that of a dominant antigen or dominant epitope;
b. obtaining one or more samples from the patient, wherein the one or more samples comprise antigen presenting cells (APCs) and peripheral blood mononuclear cells (PBMCs);
c. exposing the APCs to a peptide mix derived from one or more subdominant antigens or epitopes;
d. cultivating from the PBMCs a T cell population comprising T cells capable of recognizing said subdominant antigen or epitope by
(i) exposing the PBMCs to the APCs from step (c) in media comprising a cytokine mix consisting of IL-7 and IL-15, and lacking IL-12;
(ii) expanding the T cells in media lacking IL-6, IL-12, and IL-27, and
(iii) optionally restimulating the T cells by exposing to the APCs from step (c).